EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Janus Nanoparticles in Doxorubicin Delivery: A New Frontier in Targeted Cancer Treatment

Valeria Flores iD, Moniellen Pires Monteiro iD, Tanya Plaza, Jacobo Hernandez-Montelongo iD

Materials · 2026-04-21 · 19 (8) · 1664

DOI: 10.3390/ma19081664 ↗

At a glance

Übersichtsarbeit in Materials, published online on 2026-04-21. Written by Valeria Flores and 3 co-authors. Institution: Departamento de Bioingeniería Traslacional, Centro Universitario de Ciencias Exactas e Ingenierías (CUCEI), Universidad de Guadalajara, Guadalajara 4…. Cited 1 times so far (Crossref); 114 references. The full text is freely available (open access, CC BY 4.0). Funded by: Fondo Nacional de Desarrollo Científico y Tecnológico.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Cancer remains a primary global health challenge, accounting for millions of new cases and significant mortality annually. Although doxorubicin (DOX) is a fundamental anthracycline used for various malignancies, its therapeutic index is severely limited by poor selectivity, systemic toxicity, and dose-dependent cardiotoxicity. To address these issues, Janus nanoparticles (JNPs) have emerged as a promising bifunctional platform characterized by a structural asymmetry that allows for the independent functionalization of each hemisphere. This review examines primary fabrication routes—such as masking, microfluidics, self-assembly, and phase separation—and their specific applications in DOX delivery. The anisotropic architecture of JNPs enables a “separate rooms” concept, allowing for the co-delivery of incompatible drugs while facilitating multi-stimuli-responsive release mechanisms triggered by pH, enzymes, or NIR light. Furthermore, JNPs have demonstrated enhanced tumor accumulation and reduced systemic toxicity compared to conventional isotropic carriers. Recent developments even highlight the use of autonomous nanomotors to improve therapeutic delivery while minimizing premature leakage. However, clinical translation is currently hindered by manufacturing complexity, high equipment costs, scalability issues, and a lack of standardized reporting in the literature. Ultimately, JNPs represent a sophisticated frontier in precision oncology, though robust manufacturing processes and characterization protocols are required for future medical adoption.

Subjects

Author keywords

Janus nanoparticlescancer treatmentdoxorubicindrug delivery

Authors and institutions

  • Departamento de Bioingeniería Traslacional, Centro Universitario de Ciencias Exactas e Ingenierías (CUCEI), Universidad de Guadalajara, Guadalajara 44430, Mexico.
  • Departamento de Física, Universidad Técnica Federico Santa María, Valparaíso 2390123, Chile.
  • Departamento de Ciencias Físicas y Matemáticas, Universidad Católica de Temuco, Temuco 4813302, Chile.
  • Núcleo de Investigación en Bioproductos y Materiales Avanzados (BioMA), Universidad Católica de Temuco, Temuco 4813302, Chile.

ORCID profiles: Valeria Flores, Moniellen Pires Monteiro, Jacobo Hernandez-Montelongo

Funding

  • Fondo Nacional de Desarrollo Científico y Tecnológico

Cite

APA

Flores, V., Monteiro, M. P., Plaza, T., & Hernandez-Montelongo, J. (2026). Janus Nanoparticles in Doxorubicin Delivery: A New Frontier in Targeted Cancer Treatment. Materials, 19(8), 1664. https://doi.org/10.3390/ma19081664

Vancouver

Flores V, Monteiro MP, Plaza T, Hernandez-Montelongo J. Janus Nanoparticles in Doxorubicin Delivery: A New Frontier in Targeted Cancer Treatment. Materials. 2026;19(8):1664. doi:10.3390/ma19081664

BibTeX
@article{Flores2026,
  author = {Flores, Valeria and Monteiro, Moniellen Pires and Plaza, Tanya and Hernandez-Montelongo, Jacobo},
  title = {Janus Nanoparticles in Doxorubicin Delivery: A New Frontier in Targeted Cancer Treatment},
  journal = {Materials},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {1664},
  doi = {10.3390/ma19081664}
}
Start for free →